{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T19:29:48Z","timestamp":1793647788505,"version":"4.5.1"},"reference-count":31,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2018,9,1]]},"DOI":"10.1001\/jamaoncol.2018.1436","type":"journal-article","created":{"date-parts":[[2018,6,7]],"date-time":"2018-06-07T12:36:46Z","timestamp":1528375006000},"page":"1207","source":"Crossref","is-referenced-by-count":67,"title":["Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer"],"prefix":"10.1001","volume":"4","author":[{"given":"Naoko","family":"Matsuda","sequence":"first","affiliation":[{"name":"Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston"},{"name":"Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston"},{"name":"Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bora","family":"Lim","sequence":"additional","affiliation":[{"name":"Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston"},{"name":"Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savitri","family":"Krishnamurthy","sequence":"additional","affiliation":[{"name":"Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston"},{"name":"Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo H.","family":"Alvarez","sequence":"additional","affiliation":[{"name":"Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston"},{"name":"Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie S.","family":"Willey","sequence":"additional","affiliation":[{"name":"Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston"},{"name":"Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charla A.","family":"Parker","sequence":"additional","affiliation":[{"name":"Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston"},{"name":"Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juhee","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhua","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhui","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gildy V.","family":"Babiera","sequence":"additional","affiliation":[{"name":"Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston"},{"name":"Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L.","family":"Murray","sequence":"additional","affiliation":[{"name":"Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston"},{"name":"Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Banu K.","family":"Arun","sequence":"additional","affiliation":[{"name":"Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abenaa M.","family":"Brewster","sequence":"additional","affiliation":[{"name":"Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Reuben","sequence":"additional","affiliation":[{"name":"Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston"},{"name":"Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Stauder","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad M.","family":"Barnett","sequence":"additional","affiliation":[{"name":"Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy A.","family":"Woodward","sequence":"additional","affiliation":[{"name":"Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston"},{"name":"Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. T. Carisa","family":"Le-Petross","sequence":"additional","affiliation":[{"name":"Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston"},{"name":"Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Lucci","sequence":"additional","affiliation":[{"name":"Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston"},{"name":"Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah M.","family":"DeSnyder","sequence":"additional","affiliation":[{"name":"Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston"},{"name":"Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debu","family":"Tripathy","sequence":"additional","affiliation":[{"name":"Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente","family":"Valero","sequence":"additional","affiliation":[{"name":"Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston"},{"name":"Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto T.","family":"Ueno","sequence":"additional","affiliation":[{"name":"Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston"},{"name":"Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"2","key":"coi180029r1","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1093\/annonc\/mdt525","article-title":"Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes.","volume":"25","author":"Masuda","year":"2014","journal-title":"Ann Oncol"},{"issue":"6","key":"coi180029r2","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1093\/annonc\/mdm060","article-title":"Expression of growth factor and chemokine receptors: new insights in the biology of inflammatory breast cancer.","volume":"18","author":"Cabioglu","year":"2007","journal-title":"Ann Oncol"},{"issue":"5","key":"coi180029r3","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1093\/annonc\/mdn710","article-title":"Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer.","volume":"20","author":"Corkery","year":"2009","journal-title":"Ann Oncol"},{"issue":"4","key":"coi180029r4","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1080\/13543784.2017.1299707","article-title":"Early clinical development of epidermal growth factor receptor targeted therapy in breast cancer.","volume":"26","author":"Matsuda","year":"2017","journal-title":"Expert Opin Investig Drugs"},{"issue":"2","key":"coi180029r5","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s10549-012-2289-9","article-title":"Role of epidermal growth factor receptor in breast cancer.","volume":"136","author":"Masuda","year":"2012","journal-title":"Breast Cancer Res Treat"},{"issue":"10","key":"coi180029r6","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1371\/journal.pmed.0040315","article-title":"BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations.","volume":"4","author":"Costa","year":"2007","journal-title":"PLoS Med"},{"key":"coi180029r7","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.biochi.2014.06.011","article-title":"Epidermal growth factor\/heat shock protein 27 pathway regulates vasculogenic mimicry activity of breast cancer stem\/progenitor cells.","volume":"104","author":"Lee","year":"2014","journal-title":"Biochimie"},{"issue":"1","key":"coi180029r8","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s12032-014-0275-2","article-title":"Correlation between epidermal growth factor receptor and tumor stem cell markers CD44\/CD24 and their relationship with prognosis in breast invasive ductal carcinoma.","volume":"32","author":"Zheng","year":"2015","journal-title":"Med Oncol"},{"issue":"21","key":"coi180029r9","doi-asserted-by":"publisher","first-page":"6639","DOI":"10.1158\/1078-0432.CCR-09-0951","article-title":"Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancer.","volume":"15","author":"Zhang","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"40","key":"coi180029r10","doi-asserted-by":"crossref","first-page":"67904","DOI":"10.18632\/oncotarget.18958","article-title":"EGFR signaling promotes inflammation and cancer stem-like activity in inflammatory breast cancer.","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"issue":"4","key":"coi180029r11","doi-asserted-by":"publisher","first-page":"e228","DOI":"10.1016\/S1470-2045(17)30192-4","article-title":"Inflammatory breast cancer: a proposed conceptual shift in the UICC-AJCC TNM staging system.","volume":"18","author":"Fouad","year":"2017","journal-title":"Lancet Oncol"},{"issue":"2","key":"coi180029r12","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New Response Evaluation Criteria in Solid Tumours: revised RECIST guideline (version 1.1).","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"4","key":"coi180029r13","doi-asserted-by":"publisher","first-page":"R36","DOI":"10.1186\/gb-2013-14-4-r36","article-title":"TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions.","volume":"14","author":"Kim","year":"2013","journal-title":"Genome Biol"},{"issue":"15","key":"coi180029r14","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","article-title":"Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.","volume":"30","author":"von Minckwitz","year":"2012","journal-title":"J Clin Oncol"},{"issue":"1","key":"coi180029r15","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","article-title":"edgeR: a Bioconductor package for differential expression analysis of digital gene expression data.","volume":"26","author":"Robinson","year":"2010","journal-title":"Bioinformatics"},{"issue":"1","key":"coi180029r16","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1200\/JCO.2009.23.5101","article-title":"Neoadjuvant chemotherapy shows similar response in patients with inflammatory or locally advanced breast cancer when compared with operable breast cancer: a secondary analysis of the GeparTrio trial data.","volume":"28","author":"Costa","year":"2010","journal-title":"J Clin Oncol"},{"issue":"8","key":"coi180029r17","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1093\/annonc\/mdu183","article-title":"Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline\/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact.","volume":"25","author":"Nabholtz","year":"2014","journal-title":"Ann Oncol"},{"issue":"4","key":"coi180029r18","first-page":"abstr GS3-05","article-title":"Survival analysis of the prospectively randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy with weekly nab-paclitaxel with solvent-based paclitaxel followed by anthracycline\/cyclophosphamide for patients with early breast cancer \u2013 GBG69.","volume":"78","author":"Schneeweiss","year":"2017","journal-title":"Cancer Res"},{"issue":"3","key":"coi180029r19","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S1470-2045(15)00542-2","article-title":"Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial.","volume":"17","author":"Untch","year":"2016","journal-title":"Lancet Oncol"},{"issue":"7","key":"coi180029r20","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S1470-2045(14)70160-3","article-title":"Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.","volume":"15","author":"von Minckwitz","year":"2014","journal-title":"Lancet Oncol"},{"issue":"1","key":"coi180029r21","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1200\/JCO.2014.57.0572","article-title":"Impact of the addition of carboplatin and\/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).","volume":"33","author":"Sikov","year":"2015","journal-title":"J Clin Oncol"},{"issue":"5","key":"coi180029r22","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1080\/15384047.2015.1026481","article-title":"A phase II clinical trial of weekly paclitaxel and carboplatin in combination with panitumumab in metastatic triple negative breast cancer.","volume":"16","author":"Cowherd","year":"2015","journal-title":"Cancer Biol Ther"},{"issue":"5","key":"coi180029r23","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.clbc.2016.05.006","article-title":"Panitumumab, gemcitabine, and carboplatin as treatment for women with metastatic triple-negative breast cancer: a Sarah Cannon Research Institute phase II trial.","volume":"16","author":"Yardley","year":"2016","journal-title":"Clin Breast Cancer"},{"issue":"12","key":"coi180029r24","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1200\/JCO.2003.10.038","article-title":"Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the IDEAL 1 Trial)","volume":"21","author":"Fukuoka","year":"2003","journal-title":"J Clin Oncol"},{"issue":"16","key":"coi180029r25","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1001\/jama.290.16.2149","article-title":"Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.","volume":"290","author":"Kris","year":"2003","journal-title":"JAMA"},{"issue":"15","key":"coi180029r26","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.4161\/cbt.8.15.8939","article-title":"Caveolin-1 regulates EGFR signaling in MCF-7 breast cancer cells and enhances gefitinib-induced tumor cell inhibition.","volume":"8","author":"Agelaki","year":"2009","journal-title":"Cancer Biol Ther"},{"issue":"10","key":"coi180029r27","doi-asserted-by":"crossref","first-page":"11113","DOI":"10.18632\/oncotarget.7096","article-title":"Overexpression of lipocalin 2 in human cervical cancer enhances tumor invasion.","volume":"7","author":"Chung","year":"2016","journal-title":"Oncotarget"},{"issue":"9","key":"coi180029r28","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1002\/pros.v75.9","article-title":"Over-expression of lipocalin 2 promotes cell migration and invasion through activating ERK signaling to increase SLUG expression in prostate cancer.","volume":"75","author":"Ding","year":"2015","journal-title":"Prostate"},{"issue":"10","key":"coi180029r29","doi-asserted-by":"publisher","first-page":"3913","DOI":"10.1073\/pnas.0810617106","article-title":"Lipocalin 2 promotes breast cancer progression.","volume":"106","author":"Yang","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"27","key":"coi180029r30","doi-asserted-by":"publisher","first-page":"23631","DOI":"10.18632\/oncotarget.v6i27","article-title":"A NOX2\/Egr-1\/Fyn pathway delineates new targets for TKI-resistant malignancies.","volume":"6","author":"Irwin","year":"2015","journal-title":"Oncotarget"},{"issue":"1","key":"coi180029r31","doi-asserted-by":"publisher","first-page":"121","DOI":"10.4103\/0973-1482.151424","article-title":"Exploring the mechanism of non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitor.","volume":"12","author":"Yu","year":"2016","journal-title":"J Cancer Res Ther"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2683639","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,9,13]],"date-time":"2018-09-13T12:32:51Z","timestamp":1536841971000},"score":1,"resource":{"primary":{"URL":"http:\/\/oncology.jamanetwork.com\/article.aspx?doi=10.1001\/jamaoncol.2018.1436"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,1]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2018.1436","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9,1]]}}}